Search Results - "Rangachari, Deepa"

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches by Shea, Meghan, Costa, Daniel B., Rangachari, Deepa

“…Precision oncology is now the evidence-based standard of care for the management of many advanced non-small cell lung cancers (NSCLCs). Expert consensus has…”
Get full text

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma by Rangachari, Deepa, VanderLaan, Paul A, Shea, Meghan, Le, Xiuning, Huberman, Mark S, Kobayashi, Susumu S, Costa, Daniel B

“…Targeted somatic genomic analysis (EGFR, anaplastic lymphoma receptor tyrosine kinase gene [ALK], and ROS1) and programmed death ligand 1 (PD-L1) tumor…”
Get more information

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas by Jorge, Susan E, Lucena-Araujo, Antonio R, Yasuda, Hiroyuki, Piotrowska, Zofia, Oxnard, Geoffrey R, Rangachari, Deepa, Huberman, Mark S, Sequist, Lecia V, Kobayashi, Susumu S, Costa, Daniel B

“…exon 20 insertions account for up to 10% of all mutations in lung adenocarcinomas, representing the third most common cluster of mutations. The management of…”
Get full text

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples by Rangachari, Deepa, To, Ciric, Shpilsky, Jason E, VanderLaan, Paul A, Kobayashi, Susumu S, Mushajiang, Mierzhati, Lau, Christie J, Paweletz, Cloud P, Oxnard, Geoffrey R, Jänne, Pasi A, Costa, Daniel B

“…Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification of on-target mechanisms of resistance (i.e., EGFR C797S) to this third-generation…”
Get more information

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic? by Sehgal, Kartik, Costa, Daniel B, Rangachari, Deepa

“…Patients with lung cancer are particularly vulnerable to complications from coronavirus disease-2019 (COVID-19). Recurrent hospital visits and hospital…”
Get full text

Lung Cancer with a High Tumor Mutational Burden by VanderLaan, Paul A, Rangachari, Deepa, Costa, Daniel B, Hellmann, Matthew D, Paz-Ares, Luis

“…To the Editor: Hellmann and colleagues (May 31 issue) 1 found that tumor mutation burden assessed with the commercial assay FoundationOne CDx helped to predict…”
Get full text

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? by Sehgal, Kartik, Varkaris, Andreas, Viray, Hollis, VanderLaan, Paul A, Rangachari, Deepa, Costa, Daniel B

“…BackgroundHistological transformation of oncogene-driven lung adenocarcinoma to small cell lung cancer (SCLC) following treatment with tyrosine kinase…”
Get full text

Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: a single center analysis by DiStasio, Marcello, MD, PhD, Chen, Yigu, MPH, Rangachari, Deepa, MD, Costa, Daniel B., MD, PhD, Heher, Yael K., MD, MPH, VanderLaan, Paul A., MD, PhD

“…Abstract Introduction Molecular testing to identify targetable driver mutations is the standard of care for patients with advanced stage non-small cell lung…”
Get full text

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors by Vasconcelos, Pedro E.N.S., Gergis, Carol, Viray, Hollis, Varkaris, Andreas, Fujii, Masanori, Rangachari, Deepa, VanderLaan, Paul A., Kobayashi, Ikei S., Kobayashi, Susumu S., Costa, Daniel B.

“…The EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation (∼5% to 6% of exon 20 insertions), which, at the structural and enzyme kinetic level, more…”
Get full text

Pulmonary Resection for Isolated Pancreatic Adenocarcinoma Metastasis: an Analysis of Outcomes and Survival by Arnaoutakis, George J., Rangachari, Deepa, Laheru, Daniel A., Iacobuzio-Donahue, Chris A., Hruban, Ralph H., Herman, Joseph M., Edil, Barish H., Pawlik, Timothy M., Schulick, Richard D., Cameron, John L., Meneshian, Avedis, Yang, Stephen C., Wolfgang, Christopher L.

“…Objectives This study was conducted to determine if pulmonary metastasectomy (PM) for isolated pancreatic cancer metastases is safe and effective. Methods This…”
Get full text

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer by Piper-Vallillo, Andrew J., Halbert, Brian T., Rangachari, Deepa, Kobayashi, Susumu S., Costa, Daniel B.

Get full text

Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature by Petri, Camille R., Patell, Rushad, Batalini, Felipe, Rangachari, Deepa, Hallowell, Robert W.

“…Immune checkpoint inhibitors are known to cause a variety of immune-related adverse events, including pneumonitis. When symptomatic, treatment typically…”
Get full text

EGFR testing in advanced non-small-cell lung cancer, a mini-review by Sheikine, Yuri, MD, PhD, Rangachari, Deepa, MD, McDonald, Danielle C., NP, Huberman, Mark S., MD, Folch, Erik S., MD, MSc, VanderLaan, Paul A., MD, PhD, Costa, Daniel B., MD, PhD

“…Abstract Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor ( EGFR )…”
Get full text

Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer by Sehgal, Kartik, Peters, Mary Linton B, VanderLaan, Paul A, Rangachari, Deepa, Kobayashi, Susumu S, Costa, Daniel B

Get more information

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors by Kobayashi, Ikei S., Shaffer, William, Viray, Hollis, Rangachari, Deepa, VanderLaan, Paul A., Kobayashi, Susumu S., Costa, Daniel B.

“…Mechanisms of resistance to EGFR exon 20 insertion mutation active inhibitors have not been extensively studied in either robust preclinical models or…”
Get full text

De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors by Le, Xiuning, Desai, Neelam V, Majid, Adnan, Karp, Rebecca S, Huberman, Mark S, Rangachari, Deepa, Kent, Michael S, Gangadharan, Sidharta P, Folch, Erik, VanderLaan, Paul A, Costa, Daniel B

“…Highlights • EGFR mutations occur in some high-grade neuroendocrine lung cancers. • EGFR protein is not expressed in EGFR mutated neuroendocrine lung cancers…”
Get full text

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios by Kobayashi, Ikei S, Viray, Hollis, Rangachari, Deepa, Kobayashi, Susumu S, Costa, Daniel B

“…( ) exon 20 insertion mutations account for a tenth of all mutations in lung cancers. An important unmet clinical need is the identification of EGFR exon 20…”
Get full text

Massive Thymic Hyperplasia Masquerading as Cancer: A Case Report and Review of the Literature by Gatof, Emily Stern, Jassim, Sarmad H., Ahn, Leah, Chen, Zsu-Zsu, VanderLaan, Paul A., Rangachari, Deepa

“…A 34-year-old woman presenting with abdominal pain, chest pressure, weight loss, and tachycardia was found to have an 11.4-cm anterior mediastinal mass…”
Get full text

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience by Piper-Vallillo, A.J., Rotow, Julia K., Aredo, Jacqueline V., Shaverdashvili, Khvaramze, Luo, Jia, Carlisle, Jennifer W., Husain, Hatim, Muzikansky, Alona, Heist, Rebecca S., Rangachari, Deepa, Ramalingam, Suresh S., Wakelee, Heather A., Yu, Helena A., Sequist, Lecia V., Bauml, Joshua M., Neal, Joel W., Piotrowska, Zofia

“…This multicenter review evaluated the efficacy and safety of osimertinib dose escalation for central nervous system (CNS) progression developing on osimertinib…”
Get full text

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene by Schoepflin, Zachary R., Academia, Emmeline, Osataphan, Soravis A., Rangachari, Deepa, Sharifi, Sheida, VanderLaan, Paul A., Costa, Daniel B.

“…ALK internal deletions of nonkinase domain exons occur in 0.01% of lung cancers with ALK genomic aberrations. We report a lung adenocarcinoma with a previously…”
Get full text